Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Operating Leases (2021 - 2025)

ARS Pharmaceuticals' Operating Leases history spans 4 years, with the latest figure at $949000.0 for Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $949000.0; the TTM value through Sep 2025 reached $949000.0, changed N/A, while the annual FY2023 figure was $37000.0, 85.26% down from the prior year.
  • Operating Leases for Q3 2025 was $949000.0 at ARS Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.1 million in Q3 2021 and bottomed at $37000.0 in Q4 2023.
  • The 4-year median for Operating Leases is $949000.0 (2025), against an average of $1.7 million.
  • The largest annual shift saw Operating Leases skyrocketed 128.63% in 2022 before it plummeted 96.41% in 2023.
  • A 4-year view of Operating Leases shows it stood at $480000.0 in 2021, then plummeted by 47.71% to $251000.0 in 2022, then crashed by 85.26% to $37000.0 in 2023, then surged by 2464.86% to $949000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Operating Leases are $949000.0 (Q3 2025), $1.1 million (Q2 2025), and $37000.0 (Q4 2023).